Clinical Trials Browser

Phase 1/2 × Lymphoma × bazlitoran × Clear all

NCT02252146 2017-12-12

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

Phase 1/2 Completed

6 enrolled 7 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse